Study:
A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy
Rationale:
Estrogen can stimulate the growth of breast cancer cells. Tamoxifen may fight
breast cancer by blocking the use of estrogen. Anastrozole may fight breast cancer by
decreasing estrogen production. It is not yet known whether anastrozole is more effective
than tamoxifen in preventing the recurrence of breast cancer.
Purpose:
This randomized phase III trial is studying anastrozole to see how well it works
compared to tamoxifen in preventing the recurrence of breast cancer in postmenopausal women
with ductal carcinoma in situ who are undergoing lumpectomy and radiation therapy.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Breast Cancer |
Drug: anastrozole
Drug: tamoxifen citrate
Radiation: Radiation Therapy |
Phase 3 |
Verified by
National Surgical Adjuvant Breast and Bowel Project (NSABP)
May, 2013
Sponsored by: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Information provided by: National Surgical Adjuvant Breast and Bowel Project (NSABP)
ClinicalTrials.gov identifier: NCT00053898
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Norman Wolmark, MD., Principal Investigator